Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Hansen

Showing results (11-20 of 140) with videos related to

Pageof 14
Sort By:
Journal of the American Pharmacists Association : Japha|April 13, 2017
Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011Ning Cheng, Tannista Banerjee, Jingjing Qian, et al.
Current Psychiatry Reports|June 1, 2012
How should primary care doctors select which antidepressants to administer?Gerald Gartlehner, Kylie Thaler, Seth Hill, et al.
Clinical Therapeutics|November 18, 2005
Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertisingRichard A Hansen, Nicholas J Shaheen, Jon C Schommer
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|September 18, 2004
Resorptive drug use among community-dwelling women in MinnesotaJoel F Farley, Richard R Cline, Richard A Hansen
Research in Social & Administrative Pharmacy : RSAP|December 2, 2006
Distinguishing characteristics of patients who seek more information or request a prescription in response to direct-to-consumer advertisementsJon C Schommer, Reshmi L Singh, Richard A Hansen
Psychiatric Services (Washington, D.C.)|November 3, 2009
Impact of the STAR*D trial from the perspective of the payerAlison Little, Richard A Hansen, Gerald Gartlehner, et al.
The Annals of Pharmacotherapy|February 8, 2017
Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse EventsMd Motiur Rahman, Michael J Scalese, Richard A Hansen
Journal of Managed Care Pharmacy : JMCP|March 7, 2006
Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availabilityTroy K Trygstad, Richard A Hansen, Steven E Wegner
Drug Safety|November 18, 2009
The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysisGerald Gartlehner, Kylie Thaler, Richard A Hansen, et al.
Research in Social & Administrative Pharmacy : RSAP|June 16, 2009
Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia careRichard A Hansen, Hyunsook Chin, Susan Blalock, et al.
Pageof 14

Showing results (11-20 of 140) with videos related to

Sort By:
Pageof 14
Journal of the American Pharmacists Association : Japha|April 13, 2017
Association of authorized generic marketing with prescription drug spending on antidepressants from 2000 to 2011Ning Cheng, Tannista Banerjee, Jingjing Qian, et al.
Current Psychiatry Reports|June 1, 2012
How should primary care doctors select which antidepressants to administer?Gerald Gartlehner, Kylie Thaler, Seth Hill, et al.
Clinical Therapeutics|November 18, 2005
Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertisingRichard A Hansen, Nicholas J Shaheen, Jon C Schommer
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|September 18, 2004
Resorptive drug use among community-dwelling women in MinnesotaJoel F Farley, Richard R Cline, Richard A Hansen
Research in Social & Administrative Pharmacy : RSAP|December 2, 2006
Distinguishing characteristics of patients who seek more information or request a prescription in response to direct-to-consumer advertisementsJon C Schommer, Reshmi L Singh, Richard A Hansen
Psychiatric Services (Washington, D.C.)|November 3, 2009
Impact of the STAR*D trial from the perspective of the payerAlison Little, Richard A Hansen, Gerald Gartlehner, et al.
The Annals of Pharmacotherapy|February 8, 2017
Dipeptidyl Peptidase-4 Inhibitor-Associated Risk of Bleeding: An Evaluation of Reported Adverse EventsMd Motiur Rahman, Michael J Scalese, Richard A Hansen
Journal of Managed Care Pharmacy : JMCP|March 7, 2006
Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availabilityTroy K Trygstad, Richard A Hansen, Steven E Wegner
Drug Safety|November 18, 2009
The general and comparative efficacy and safety of duloxetine in major depressive disorder: a systematic review and meta-analysisGerald Gartlehner, Kylie Thaler, Richard A Hansen, et al.
Research in Social & Administrative Pharmacy : RSAP|June 16, 2009
Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia careRichard A Hansen, Hyunsook Chin, Susan Blalock, et al.
Pageof 14